The DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.
Immunoglobulin light chain amyloidosis: 2014 update on diagnosis, prognosis, and treatment
Abstract
Disease Overview: Immunoglobulin light chain amyloidosis is a clonal, nonproliferative plasma cell disorder in which fragments of immunoglobulin light chain are deposited in tissues. Clinical features depend on organs involved but can include restrictive cardiomyopathy, nephrotic syndrome, hepatic failure, peripheral/autonomic neuropathy, and atypical multiple myeloma. Diagnosis: Tissue biopsy stained with Congo red demonstrating amyloid deposits with apple‐green birefringence is required for diagnosis. Invasive organ biopsy is not required because amyloid deposits can be found in bone marrow biopsy or subcutaneous fat aspirate in 85% of patients. Verification that amyloid is composed of immunoglobulin light chains is mandatory. Prognosis: N‐terminal pro‐brain natriuretic peptide (NT‐proBNP), serum troponin T, and difference between involved and uninvolved immunoglobulin free light chain values are used to classify patients into four groups of similar size; median survivals are 94.1, 40.3, 14.0, and 5.8 months. Therapy: All patients with a systemic amyloid syndrome require therapy to prevent deposition of amyloid in other organs and prevent progressive organ failure of involved sites. Stem cell transplant (SCT) is preferred, but only 20% of patients are eligible. Requirements for safe SCT include NT‐proBNP <5,000 ng/mL, troponin T <0.06 ng/mL, age <70 years, <3 organs involved, and serum creatinine ≤1.7 mg/dL. Nontransplant candidates can be offered melphalan–dexamethasone or cyclophosphamide–bortezomib–dexamethasone. Other combinations of chemotherapy with agents such as cyclophosphamide–thalidomide (or lenalidomide)–dexamethasone, bortezomib–dexamethasone, and melphalan–prednisone–lenalidomide have documented activity. Future Challenges: Late diagnosis remains a major obstacle to initiating effective therapy. Recognizing the presenting syndromes is necessary for improving survival.Am. J. Hematol. 89:1133–1140, 2014. © 2014 Wiley Periodicals, Inc.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Review of 1027 Patients With Newly Diagnosed Multiple Myeloma
Kyle, R. A., Gertz, M. A., Witzig, T. E., Lust, J. A., Lacy, M. Q., Dispenzieri, A., Fonseca, R., Rajkumar, S. V., Offord, J. R., Larson, D. R., et al. (2003) · Mayo Clinic Proceedings · doi:10.4065/78.1.21 · Cited by 2,447
Self-citationPrevalence of monoclonal gammopathy of undetermined significance
Kyle, R. A., Therneau, T. M., Rajkumar, S. V., Larson, D. R., Plevak, M. F., Offord, J. R., Dispenzieri, A., Katzmann, J. A., & Melton, L. J. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa054494 · Cited by 1,423 · cited 1×
“The percentage of each type of M protein is shown in samples from patients with MGUS [21], myeloma [22], and AL amyloidosis [23].”
Dispenzieri, A., Kyle, R., Merlini, G., Miguel, J. S., Ludwig, H., Hajek, R., Palumbo, A., Jagannath, S., Blade, J., Lonial, S., et al. (2009) · Leukemia · doi:10.1038/leu.2008.307 · Cited by 815 · cited 1×
“serum [18], immunofixation of the urine [19], and an Ig free light chain (FLC) assay [20].”
Self-citation
Cited by
Chemotherapy-induced peripheral neuropathy: a current review
Staff, N. P., Grisold, A., Grisold, W., & Windebank, A. J. (2017) · Annals of Neurology · doi:10.1002/ana.24951 · Cited by 908
Prevalence and Outcomes of Concomitant Aortic Stenosis and Cardiac Amyloidosis
Nitsche, C., Scully, P. R., Patel, K. P., Kammerlander, A. A., Koschutnik, M., Dona, C., Wollenweber, T., Ahmed, N., Thornton, G. D., Kelion, A. D., et al. (2021) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2020.11.006 · Cited by 377
The Pathology of Amyloidosis in Classification: A Review
Picken, M. M. (2020) · Acta Haematologica · doi:10.1159/000506696 · Cited by 313
Light Chain Amyloidosis: Patient Experience Survey from the Amyloidosis Research Consortium
Lousada, I., Comenzo, R. L., Landau, H., Guthrie, S., & Merlini, G. (2015) · Advances in Therapy · doi:10.1007/s12325-015-0250-0 · Cited by 269
Goto, S., Mahara, K., Beussink-Nelson, L., Ikura, H., Katsumata, Y., Endo, J., Gaggin, H. K., Shah, S. J., Itabashi, Y., MacRae, C. A., et al. (2021) · Nature Communications · doi:10.1038/s41467-021-22877-8 · Cited by 245
Metadata
- Authors
- Gertz, M. A.
- Venue
- American Journal of Hematology
- Publisher
- Wiley
- Published
- 2014-11-19
- Volume
- 89
- Issue
- 12
- Pages
- 1132-1140
- ISSN
- 0361-8609 (ISSN-L)
- 1096-8652
- OpenAlex
- W2086218597
- Cited by
- 245
- References
- 3
- FWCI
- 9.00
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Immunoglobulin light chain amyloidosis: 2014 update on diagnosis, prognosis, and treatment. https://app.cochat.ai/papers/10.1002/ajh.23828
- The paper
- Gertz, M. A. (2014). Immunoglobulin light chain amyloidosis: 2014 update on diagnosis, prognosis, and treatment. American Journal of Hematology. https://doi.org/10.1002/ajh.23828
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.